102 related articles for article (PubMed ID: 35568624)
1. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma.
Sun Z; Liu M
Cytotherapy; 2022 Sep; 24(9):940-953. PubMed ID: 35568624
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.
Elgohary G; Yang Y; Gergis M; Yi D; Gergis U
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e142-e151. PubMed ID: 38267353
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.
Lv L; Wu Y; Shi H; Sun X; Deng Z; Huo H; Li R; Liu Y
Cancer Immunol Immunother; 2023 Jan; 72(1):211-221. PubMed ID: 35796863
[TBL] [Abstract][Full Text] [Related]
5. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
Jain MD; Jacobs MT; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos D; Neelapu SS; Locke FL; Ghobadi A
Blood Adv; 2024 Feb; 8(4):1042-1050. PubMed ID: 38051550
[TBL] [Abstract][Full Text] [Related]
6. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C; Neill L; Osborne W; Iyengar S; Tholouli E; Irvine D; Chaganti S; Besley C; Bloor A; Jones C; Uttenthal B; Johnson R; Sanderson R; Cheok K; Marzolini M; Townsend W; O'Reilly M; Kirkwood AA; Kuhnl A
Blood Adv; 2023 Jun; 7(12):2872-2883. PubMed ID: 36724512
[TBL] [Abstract][Full Text] [Related]
7. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Zafar A; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Martin TG; Shah N; Banerjee R
Transplant Cell Ther; 2023 Aug; 29(8):504.e1-504.e7. PubMed ID: 37244643
[TBL] [Abstract][Full Text] [Related]
8. Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients.
Zhou Y; Mu W; Wang C; Zhuo Z; Xin Y; Li H; Wang C
BMC Cancer; 2023 Oct; 23(1):1019. PubMed ID: 37872514
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.
Nath K; Tomas AA; Flynn J; Fein JA; Alperovich A; Anagnostou T; Batlevi CL; Dahi PB; Fingrut WB; Giralt SA; Lin RJ; Palomba ML; Peled JU; Salles G; Sauter CS; Scordo M; Fraint E; Feuer E; Shah N; Slingerland JB; Devlin S; Shah GL; Gupta G; Perales MA; Shouval R
Transplant Cell Ther; 2022 Nov; 28(11):751.e1-751.e7. PubMed ID: 35944603
[TBL] [Abstract][Full Text] [Related]
10. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.
Trottmann M; Blozik E; Hilbig M; LoVerdi D; Pedruzzi M; Scherer T; Weiss M; Pletscher M; Meier N
Swiss Med Wkly; 2023 Sep; 153():3441. PubMed ID: 37774383
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
Wang TP; Ahn KW; Shadman M; Kaur M; Ahmed N; Bacher U; Cerny J; Chen A; Epperla N; Frigault M; Grover N; Haverkos B; Hill B; Hossain N; Iqbal M; Jain T; Krem MM; Maakaron J; Modi D; Alhaj Moustafa M; Riedell P; Savani B; Sica RA; Sureda A; Wudhikarn K; Herrera AF; Sauter C; Hamadani M; Jimenez Jimenez A
Leukemia; 2024 May; ():. PubMed ID: 38750138
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis.
Jang JK; Pyo J; Suh CH; Park HS; Chae YK; Kim KW
Front Oncol; 2022; 12():851877. PubMed ID: 35692797
[TBL] [Abstract][Full Text] [Related]
13. The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.
Xia Y; Tang L; Hu Y
Technol Health Care; 2023; 31(6):2363-2380. PubMed ID: 37545264
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
Kim J; Cho J; Lee MH; Yoon SE; Kim WS; Kim SJ
Blood; 2024 May; ():. PubMed ID: 38696731
[TBL] [Abstract][Full Text] [Related]
15. Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy: a meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Bindal P; Patell R; Chiasakul T; Lauw MN; Ko A; Wang TF; Zwicker JI
J Thromb Haemost; 2024 Apr; ():. PubMed ID: 38574863
[TBL] [Abstract][Full Text] [Related]
16. Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
Boyle S; Roddie C; O'Reilly M; Menne T; Norman J; Gibb A; Lugthart S; Chaganti S; Gonzalez Arias C; Jones C; Latif A; Uttenthal BJ; Seymour F; Osborne W; Springell D; Hardefeldt P; Yallop D; Thoulouli E; Bloor A; Besley C; Mathew A; Burns D; Cwynarski K; Sanderson R; Kuhnl A
Br J Haematol; 2024 Feb; 204(2):507-513. PubMed ID: 37848384
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
Mahmood SS; Riedell PA; Feldman S; George G; Sansoterra SA; Althaus T; Rehman M; Mead E; Liu JE; Devereux RB; Weinsaft JW; Kim J; Balkan L; Barbar T; Lee Chuy K; Harchandani B; Perales MA; Geyer MB; Park JH; Palomba ML; Shouval R; Tomas AA; Shah GL; Yang EH; Gaut DL; Rothberg MV; Horn EM; Leonard JP; Van Besien K; Frigault MJ; Chen Z; Mehrotra B; Neilan TG; Steingart RM
Eur Heart J; 2023 Jun; 44(22):2029-2042. PubMed ID: 36939851
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review.
Al-Ibraheem A; Abdlkadir AS; Lopci E; Allouzi S; Paez D; Alkuwari M; Makoseh M; Novruzov F; Usmani S; Al-Rabi K; Mansour A
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730680
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy.
Dou B; Ren S; Qiu L; Zhang X; Zhang N; Cai J; Chen D; Zhang Q; Yao H; Fan F
Front Med (Lausanne); 2023; 10():1265835. PubMed ID: 38264058
[TBL] [Abstract][Full Text] [Related]
20. How I treat cytopenias after CAR T-cell therapy.
Jain T; Olson TS; Locke FL
Blood; 2023 May; 141(20):2460-2469. PubMed ID: 36800563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
